Objective: Examining the effects of simvastatin on skeletal muscles in an experimental model of abdominal sepsis in rats through the biodistribution of 99mTc-sestamibi. Methods: Wistar rats were randomly assigned to 2 groups: with abdominal sepsis (n = 12) and without sepsis (n = 12). Six animals with sepsis and 6 controls were injected with a daily dose of 5 mg/kg/day of simvastatin by gavage for 3 days before induction of peritonitis and 4 hours before surgical procedure. The others received 1ml of 0.9% saline solution orally. The animals were anesthetized with 20mg/kg of xylazine and 50mg/kg of ketamine i.p. Cecal ligation and puncture were performed by laparotomy. The rats were under observation for 24 hours and their survival time was recorded. The animals were re-anesthetized and 0.1 ml of 99mTc-sestamibi was administered by i.v. 30 minutes later,the thigh muscle was biopsied for percentage of radioactivity per gram of tissue (ATI%/g) determination, measured by the automatic gamma counter Wizard Counter, PerkinElmer,Finland. Results: ATI%/g of Tc99m-sestamibi was higher in muscle samples of groups treated with simvastatin sepsis ((1.820.21), compared with saline-treated (1.070.19) and control groups (1.180.31;1.260.24); this is a statistically significant difference (p<0.001). Conclusion: The data resulting from this study allows for concluding that the pre-treatment with simvastatin contributed to a biodistribution increase of 99mTc-sestamibi into the skeletal muscle in the abdominal sepsis model in rats. 
INTRODUCTION
In 1976, the first statin was discovered, mevastatin, isolated from antibiotic derivative compounds. Its major function is inactivating HMG-CoA reductase (enzyme responsible for synthesizing cholesterol) 1 , and it was able to influence the appearance of new research for the discovery of other family drugs that promote the reduction of serum cholesterol levels.
Subsequent studies demonstrated pleiotropism of statins, revealing antiinflammatory action by inhibiting thrombogenesis, and even immunomodulatory . This occurs through an imbalance in the endothelial-leukocyte cell interaction caused by the drug, regardless of their anti-cholesterolemic actions 5, 6 . The persistence of infectious processes, such as those caused by S. aureus, is capable of generating a systemic inflammatory response, and may develop into sepsis.
This condition may be the cause of muscle loss and this has been observed in mouse models of sepsis experimentally induced by cecal ligation and puncture (CLP), which causes a focus of necrotic tissue and polimicrobial contamination of the peritoneal cavity 7 .
Sepsis promotes increased proteolysis of skeletal muscle, a phenomenon that occurs when there is an imbalance between protein synthesis and degradation, as reflected by inhibition of protein synthesis together with the increase of its degradation.
The elevated levels of various cytokines such as tumor necrosis factor (TNF-α) and interleukin-6 during sepsis may influence muscle damage and protein degradation 8 .
Thus, based on the evidence of the harmful effects of sepsis on skeletal muscles and anti-inflammatory effects of statins on the myocardium in a septicemic
context, the present study tested the hypothesis that treatment with simvastatin during sepsis promotes anti-inflammatory effects on the skeletal muscle, using rats as the experimental model. 
METHODS
We performed a study with experimental design using 24 Wistar rats randomly separated into two groups. Twelve septic animals and 12 controls (without sepsis) were kept in individual cages with water and standard rodent feed ad libitum (Presence®), after previously experiencing a period of 7 days of acclimation to the laboratory. They 
Experimental Design
As shown in the diagram below, half of the animals were orally treated with simvastatin and the other half with 0.9%saline solution. Six animals with sepsis and 6 controls were injected with a daily dose of 5 mg/kg/day of simvastatin suspension by gavage for 3 days before induction of peritonitis and 4 hours before surgery (CLP). The remaining animals were orally treated with 1 ml of 0.9% saline solution. 
Biodistribution of 99mTc-sestamibi in skeletal muscles
All animals were anesthetized with the same technique described above in the 
Statistical Analysis
Data were analyzed quantitatively and a description including measures of central tendency was performed (mean and standard deviation). Analysis of variance and Tukey test for inferences were performed, with statistical significance of p<0.05. There were no significant differences in 99mTc-sestamibi percentage of the activity in skeletal muscle among the control groups treated with simvastatin and with saline solution. The activity percentage of the 99mTc-sestamibi per gram of tissue was
RESULTS
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shown to be significantly higher in the muscle samples of sepsis group treated with simvastatin, when compared with the sepsis group treated with saline and control groups (Table 1) . Consequently, the muscle perfusion as measured by ATI%/g of 99mTc-sestamibi in the thigh muscle of the animals was significantly higher in the sepsis group pre-treated with simvastatin than in the sepsis group without simvastatin treatment. It was also significantly higher than in animals of the control groups treated with or without simvastatin. In a study by our group, we evaluated the action of simvastatin in septic rats in relation to dosages of cytokines, and found that there was a significant reduction in the levels of TNF-α, IL-1β and IL-6 in animals with sepsis when simvastatin was administered, demonstrating a significant anti-inflammatory effect this drug 13 . This evidence corroborates the positive results in skeletal muscle sepsis in rats observed in the results of this research.
DISCUSSION
Liappis et al has shown that the anti-inflammatory effect of statins is probably responsible for the low mortality in patients with bacteremia who received these drugs.
It means that the effect of statins originates from various actions (inhibition of the expression of essential adhesion molecules in leukocyte/endothelial connection and control chemotactic proteins, for example) 14 . Importantly, mortality triggered by sepsis is intrinsically related to the inflammatory response and cytokine production [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
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In order to evaluate the anti-inflammatory response of simvastatin on skeletal muscle, this study used the radioactive tracer 99mTc-sestamibi, whose tissue penetration depends on the negative plasma potential to be conducted, of the mitochondrial integrity where it should be focused, and of the normal metabolic condition of cells 10, 18 .
Metabolic and hemodynamic changes caused by the inflammatory process of sepsis can lead to tissue ischemia, which interferes with the K+/ATPase mitochondrial channels, leading to alteration of mitochondrial membrane potential. Thus, Tc99m-sestamibi does not accumulate in this organelle, to the point that it is not significantly detected in ischemic tissue.
Although there is evidence that statins cause side effects related to the skeletal muscle in prolonged use, such as rhabdomyolysis, myalgia, muscle cramps, weakness and muscle pain in patients using long-term simvastatin 19, 20 , this study evaluated its use in the acute treatment of sepsis, which showed anti-inflammatory relevance in detriment to any deleterious effects.
The data resulting from this study allow us to conclude that the pre-treatment with simvastatin contributed to the biodistribution increase of 99mTc-sestamibi into skeletal muscle tissue, in an abdominal sepsis model in rats. Given that this radiopharmaceutical evaluates muscle perfusion, our results open opportunity for future research aimed at muscle perfusion in sepsis with the use of other assessment methods.
